VIVUS, Inc. recently announced that the QsymiaTM (phentermine and topiramate extended-release) capsules led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these associated conditions. The improvements were significantly greater among patients who lost 10% or more of their starting weight. The study was published online in The American Journal of Cardiology and can be accessed via the following link: [http://www.ajconline.org/article/S0002-9149(12)02641-0/abstract].
“This provides clear evidence that patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors,” said Suzanne Oparil , M.D., Director of the Vascular Biology and Hypertension Program, University of Alabama at Birmingham, and an investigator in the study. “The ability to improve underlying risk factors is another reason physicians should proactively discuss the medical treatment of obesity with their patients who have failed lifestyle modification alone.”
Obesity is a chronic condition defined by having excess body fat. Obesity and smoking are the leading causes of preventable death in the U.S., and obesity contributes directly to numerous life-threatening conditions including diabetes, cardiovascular disease, hypertension and stroke. According to the World Health Organization and CDC, more than 500 million people worldwide and approximately one-third of American adults (more than 78 million people) are obese. In addition to obesity, high cholesterol, blood pressure and triglycerides are significant risk factors for cardiovascular disease.
Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.